Unlocking the global market to eliminate viral Hepatitis

Focus on partnering for innovation to diagnose Hepatitis C

At the AASLD Liver Meeting, Boston, USA


The Foundation for Innovative New Diagnostics (FIND), a non-profit foundation, provides affordable innovative diagnostic products for developing countries. 


The AASLD Liver Meeting organized by the American Association for the Study of Liver Diseases (AASLD) annually assembles more than 9 500 health professionals, as well as private and public stakeholders from the US and the world to exchange leading-edge research and discuss treatment outcomes. At the occasion of The Liver Meeting, together with FIND and HIV Forum’s HCV Drug Development Advisory Group, GD helped convene and co-host an industry-focused strategic meeting “Hepatitis C Diagnostics – the Bottleneck to Unlocking a Global Market” enabling innovation and partnerships with the pharmaceutical and diagnostic industries. GD president Barbara Bulc moderated the event, together with the co-hosts, to provide systems perspectives on how to unlock the global market and end Hepatitis C. Optimal strategies were determined for new diagnostic tests to drive access to treatment and care for hepatitis C in limited-resource settings.


  • Established FIND as the recognized key global player and convener to accelerate the scale up of new affordable diagnostics solutions for Hepatitis C
  • Incubated collaborations between leaders from the pharmaceutical and diagnostics industries to align objectives, product development and market access projects towards the elimination of Hepatitis C


Additional Resources: 

HIV Forum Press Release

The AASLD Liver Meeting

About FIND